CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug Application for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- 3 Penny Stocks to Watch Now, 11/24/24
- CERo Therapeutics’ (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data
- Cero Therapeutics presents preclinical data on CER-1236
- Cero Therapeutics files to sell 713.56M shares of common stock for holders
- Cero Therapeutics submits IND clinical hold CRL to the FDA
Questions or Comments about the article? Write to editor@tipranks.com